USANA HEALTH SCIENCES, INC. (USNA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-07-04..
- Stock-based compensation / revenue · 12 months: Value 1.55%; Formula and calculation Share-based compensation / revenue. Period ending 2026-07-04..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-04; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-07-04. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.55% | Share-based compensation / revenue. Period ending 2026-07-04. $14.18M ÷ $913.36M × 100 ≈ 1.55% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 913.36M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.18M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -1.08M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-04 | (m) | $913.36M | $14.18M | $-1.08M | (m) | (m) | 1.55% | (m) | (m) |
| 2026-04-04 | (m) | $925.94M | $14.40M | $35.63M | (m) | (m) | 1.56% | (m) | (m) |
| 2026-01-03 | $10.69M | $925.26M | $13.83M | $37.43M | (m) | 1.16% | 1.49% | (m) | (m) |
| 2025-09-27 | (m) | $912.67M | $13.69M | $41.82M | (m) | (m) | 1.50% | (m) | (m) |
| 2025-06-28 | (m) | $899.22M | $13.66M | $56.20M | (m) | (m) | 1.52% | (m) | (m) |
| 2025-03-29 | (m) | $876.24M | $13.77M | $57.32M | (m) | (m) | 1.57% | (m) | (m) |
| 2024-12-28 | $11.57M | $854.50M | $14.56M | $66.32M | (m) | 1.35% | 1.70% | (m) | (m) |
| 2024-09-28 | (m) | $861.97M | $14.59M | $82.33M | (m) | (m) | 1.69% | (m) | (m) |
| 2024-06-29 | (m) | $875.12M | $14.72M | $84.34M | (m) | (m) | 1.68% | (m) | (m) |
| 2024-03-30 | (m) | $900.45M | $14.66M | $90.90M | $283.00K | (m) | 1.63% | 321.20× | Reported |
| 2023-12-30 | $11.45M | $921.01M | $14.60M | $93.07M | $262.00K | 1.24% | 1.58% | 355.23× | Reported |
| 2023-09-30 | (m) | $927.89M | $14.47M | $91.40M | $149.00K | (m) | 1.56% | 613.44× | Reported |
| 2023-07-01 | (m) | $947.82M | $13.87M | $96.43M | $138.00K | (m) | 1.46% | 698.74× | Reported |
| 2023-04-01 | (m) | $974.09M | $13.76M | $101.39M | $191.00K | (m) | 1.41% | 530.85× | Reported |
| 2022-12-31 | $11.56M | $998.60M | $13.33M | $107.61M | $192.00K | 1.16% | 1.33% | 560.49× | Reported |
| 2022-10-01 | (m) | $1.04B | $13.07M | $116.57M | $178.00K | (m) | 1.26% | 654.88× | Reported |
| 2022-07-02 | (m) | $1.08B | $13.45M | $134.71M | $164.00K | (m) | 1.25% | 821.39× | Reported |
| 2022-04-02 | (m) | $1.15B | $13.74M | $159.06M | $84.00K | (m) | 1.19% | 1893.60× | Reported |
| 2022-01-01 | $11.11M | $1.19B | $14.30M | $170.19M | $57.00K | 0.94% | 1.21% | 2985.82× | Reported |
| 2021-10-02 | (m) | $1.23B | $14.91M | $191.22M | $-1.07M | (m) | 1.21% | (m) | Reported |
| 2021-07-03 | (m) | $1.25B | $14.99M | $195.81M | $290.00K | (m) | 1.20% | 675.21× | Reported |
| 2021-04-03 | (m) | $1.18B | $14.74M | $181.68M | $491.00K | (m) | 1.25% | 370.01× | Reported |
| 2021-01-02 | $10.63M | $1.13B | $14.39M | $176.49M | $507.00K | 0.94% | 1.27% | 348.11× | Reported |
| 2020-09-26 | (m) | $1.10B | $13.38M | $168.52M | $1.64M | (m) | 1.22% | 102.95× | Reported |
| 2020-06-27 | (m) | $1.06B | $13.93M | $158.63M | $282.00K | (m) | 1.32% | 562.51× | Reported |
| 2020-03-28 | (m) | $1.05B | $15.10M | $150.20M | $75.00K | (m) | 1.43% | 2002.64× | Reported |
| 2019-12-28 | $10.26M | $1.06B | $15.54M | $146.19M | $66.00K | 0.97% | 1.46% | 2215.00× | Reported |
| 2019-09-28 | (m) | $1.09B | $16.61M | $150.19M | $53.00K | (m) | 1.53% | 2833.72× | Reported |
| 2019-06-29 | (m) | $1.12B | $16.50M | $160.24M | $39.00K | (m) | 1.47% | 4108.79× | Reported |
| 2019-03-30 | (m) | $1.17B | $14.98M | $180.23M | $38.00K | (m) | 1.28% | 4742.84× | Reported |
| 2018-12-29 | $10.24M | $1.19B | $14.96M | $188.35M | $36.00K | 0.86% | 1.26% | 5232.03× | Reported |
| 2018-09-29 | (m) | (m) | $14.80M | $175.68M | $42.00K | (m) | (m) | 4182.79× | Reported |
| 2018-06-30 | (m) | (m) | $14.54M | $161.52M | $44.00K | (m) | (m) | 3670.91× | Reported |
| 2018-03-31 | (m) | (m) | $15.09M | $142.75M | $46.00K | (m) | (m) | 3103.17× | Reported |
| 2017-12-30 | $8.95M | (m) | $15.48M | $132.50M | $46.00K | (m) | (m) | 2880.52× | Reported |
| 2017-09-30 | (m) | (m) | $14.29M | $128.45M | $51.00K | (m) | (m) | 2518.59× | Reported |
| 2017-07-01 | (m) | (m) | $15.12M | $132.92M | $87.00K | (m) | (m) | 1527.86× | Reported |
| 2017-04-01 | (m) | (m) | $16.13M | $138.00M | $252.00K | (m) | (m) | 547.64× | Reported |
| 2016-12-31 | $8.84M | (m) | $16.54M | $138.62M | $444.00K | (m) | (m) | 312.21× | Reported |
| 2016-10-01 | (m) | (m) | $18.09M | $141.92M | $428.00K | (m) | (m) | 331.60× | Reported |
| 2016-07-02 | (m) | (m) | $16.11M | $144.06M | $386.00K | (m) | (m) | 373.20× | Reported |
| 2016-04-02 | (m) | (m) | $13.48M | $145.38M | $217.00K | (m) | (m) | 669.95× | Reported |
| 2016-01-02 | $6.42M | (m) | $11.08M | $141.66M | $15.00K | (m) | (m) | 9444.13× | Reported |
| 2015-10-03 | (m) | (m) | $10.83M | $139.16M | $129.00K | (m) | (m) | 1078.78× | Reported |
| 2015-07-04 | (m) | (m) | $10.12M | $130.45M | $130.00K | (m) | (m) | 1003.48× | Reported |
| 2015-04-04 | (m) | (m) | $10.18M | $120.77M | (m) | (m) | (m) | (m) | (m) |
| 2015-01-03 | $5.13M | (m) | $9.80M | $116.10M | $129.00K | (m) | (m) | 900.02× | Reported |
| 2014-09-27 | (m) | (m) | $7.44M | $112.47M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-28 | (m) | (m) | $7.27M | $107.91M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-29 | (m) | (m) | $7.09M | $115.27M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-28 | $5.08M | (m) | $7.62M | $116.71M | $1.00K | (m) | (m) | 116712.00× | Reported |
| 2013-09-28 | (m) | (m) | $8.14M | $115.79M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-29 | (m) | (m) | $9.02M | $115.18M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-30 | (m) | (m) | $9.71M | $103.88M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-29 | $4.66M | (m) | $10.21M | $98.18M | $20.00K | (m) | (m) | 4908.95× | Reported |
| 2012-09-29 | (m) | (m) | $10.99M | $90.20M | $11.00K | (m) | (m) | 8199.64× | Reported |
| 2012-06-30 | (m) | (m) | $11.37M | $84.89M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $10.18M | $80.89M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $10.55M | $77.26M | $9.00K | (m) | (m) | 8584.00× | Reported |
| 2011-10-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-01-01 | (m) | (m) | $10.41M | $68.22M | $94.00K | (m) | (m) | 725.70× | Reported |
| 2010-10-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-01-02 | (m) | (m) | $8.93M | $50.79M | $609.00K | (m) | (m) | 83.40× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |